Last reviewed 2026-04-23 · How we verify

Placebo of clopidogrel and Asprin

This is a placebo control arm containing inactive formulations of clopidogrel and aspirin used in a clinical trial to establish efficacy of the active antiplatelet agents.

This is a placebo control arm containing inactive formulations of clopidogrel and aspirin used in a clinical trial to establish efficacy of the active antiplatelet agents. Used for Control arm in phase 3 trial evaluating dual antiplatelet therapy (likely acute coronary syndrome, stroke prevention, or stent thrombosis prevention).

At a glance

Mechanism of action

Placebo formulations are designed to be indistinguishable from active clopidogrel and aspirin but contain no pharmacologically active ingredients. They serve as the control comparator in phase 3 trials to measure the true clinical benefit of dual antiplatelet therapy (DAPT) by accounting for placebo effect and natural disease progression.

Approved indications

• Control arm in phase 3 trial evaluating dual antiplatelet therapy (likely acute coronary syndrome, stroke prevention, or stent thrombosis prevention)

Common side effects

No common side effects on file.

Key clinical trials

• Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebo of clopidogrel and Asprin CI brief — competitive landscape report
• Placebo of clopidogrel and Asprin updates RSS · CI watch RSS
• Beijing Tiantan Hospital portfolio CI